Evidence map›Paper›PMID 34443100›Full record

ArticleMaterials (Basel, Switzerland)2021

One-Step Microwave-Assisted Synthesis and Visible-Light Photocatalytic Activity Enhancement of BiOBr/RGO Nanocomposites for Degradation of Methylene Blue.

Kun-Yauh Shih, Yen-Ling Kuan, En-Rui Wang

Abstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. One-Pot Synthesis of SnOPolymers · 2022
    Article
  2. Microwave-Assisted Rapid Synthesis of Eu(OH)Materials (Basel, Switzerland) · 2021
    Article
  3. Facile Microwave Hydrothermal Synthesis of ZnFeMaterials (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kun-Yauh ShihDepartment of Applied Chemistry, National Pingtung University, Pingtung 90003, Taiwan.
Yen-Ling KuanDepartment of Applied Chemistry, National Pingtung University, Pingtung 90003, Taiwan.
En-Rui WangDepartment of Applied Chemistry, National Pingtung University, Pingtung 90003, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, bismuth oxybromide/reduced graphene oxide (BiOBr/RGO), i.e. BiOBr-G nanocomposites, were synthesized using a one-step microwave-assisted method. The structure of the synthesized nanocomposites was characterized using Raman spectroscopy, X-ray diffractometry (XRD), photoluminescence (PL) emission spectroscopy, scanning electron microscopy (SEM), transmission electron microscopy (TEM), Fourier-transform infrared spectroscopy (FTIR), and ultraviolet-visible diffuse reflection spectroscopy (DRS). In addition, the ability of the nanocomposite to degrade methylene blue (MB) under visible light irradiation was investigated. The synthesized nanocomposite achieved an MB degradation rate of above 96% within 75 min of continuous visible light irradiation. In addition, the synthesized BiOBr-G nanocomposite exhibited significantly enhanced photocatalytic activity for the degradation of MB. Furthermore, the results revealed that the separation of the photogenerated electron-hole pairs in the BiOBr-G nanocomposite enhanced the ability of the nanocomposite to absorb visible light, thus improving the photocatalytic properties of the nanocomposites. Lastly, the MB photo-degradation mechanism of BiOBr-G was investigated, and the results revealed that the BiOBr-G nanocomposites exhibited good photocatalytic activity.

Indexed as

bismuth oxybromidegraphenemicrowave-assisted synthesisnanocompositesphotocatalytic activity

Identifiers

PMID34443100
PMCPMC8401011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.